Good morning, you're listening to Markets Desk.
UnitedHealth is the standout mover in healthcare today, with shares rallying sharply after the insurer beat earnings estimates and raised its profit outlook for the second time this year. The company is cutting unprofitable contracts, shrinking membership deliberately, and deploying one point five billion dollars into AI to compress costs — a disciplined turnaround story that the market is rewarding.
Shifting to pharma, Eli Lilly is acquiring psychedelics developer AtaiBeckley for two point eight billion dollars, gaining access to experimental compounds including DMT and MDMA. This signals that major pharmaceutical houses are no longer treating psychedelic-assisted therapy as fringe science — Lilly is placing a serious capital bet that these pipelines become approved treatments within the decade.
And in venture capital, a sobering note for anyone dreaming of early-stage AI returns. With Anthropic and its peers carrying stratospheric valuations, the math for venture investors has fundamentally changed. Entry prices are so elevated that the multiples needed to generate fund-returning outcomes are increasingly difficult to achieve — even when you back the right company.
That's the tape. Markets Desk, signing off the floor.
